The UMBRELLA SIOP–RTSG 2016 Wilms tumour pathology and molecular biology protocol

Bilateral Wilms tumour: a review of clinical and molecular features

(2017) Jocelyn Charlton et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor

(2017) Samantha Gadd et al.   NATURE GENETICS

Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

(2017) Marry M. van den Heuvel-Eibrink et al.   Nature Reviews Urology

Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience

(2017) Gordan M. Vujanić et al.   PEDIATRIC BLOOD & CANCER

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group

(2016) Ariadne H.A.G. Ooms et al.   CLINICAL CANCER RESEARCH

Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations

(2016) Mariana M. Cajaiba et al.   HUMAN PATHOLOGY

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

(2016) Tasnim Chagtai et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group

(2016) Eric J. Gratias et al.   JOURNAL OF CLINICAL ONCOLOGY

Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications

(2016) George D. Cresswell et al.   EBioMedicine

Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors

(2015) Amy L. Walz et al.   CANCER CELL

Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors

(2015) Jenny Wegert et al.   CANCER CELL

Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)

(2015) M.M. van den Heuvel-Eibrink et al.   EUROPEAN JOURNAL OF CANCER

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

(2015) Kathy Pritchard-Jones et al.   LANCET

Current Concepts in Surgery for Wilms Tumor—The Risk and Function-Adapted Strategy

(2014) Norbert Graf et al.   EUROPEAN JOURNAL OF PEDIATRIC SURGERY

Pretreatment for Bilateral Nephroblastomatosis is an Independent Risk Factor for Progressive Disease in Patients with Stage V Nephroblastoma

(2014) R. Furtwängler et al.   KLINISCHE PADIATRIE

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia

(2014) Mariana Maschietto et al.   PLoS One

Malformations, genetic abnormalities, and wilms tumor

(2013) S. Dumoucel et al.   PEDIATRIC BLOOD & CANCER

Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial

(2012) K. Pritchard-Jones et al.   ANNALS OF ONCOLOGY

Nephrological findings and genotype–phenotype correlation in Beckwith–Wiedemann syndrome

(2011) Alessandro Mussa et al.   PEDIATRIC NEPHROLOGY

Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group

(2010) Marry M. van den Heuvel-Eibrink et al.   PEDIATRIC BLOOD & CANCER

Central pathology review in multicenter trials and studies

(2009) Gordan M. Vujanić et al.   CANCER

The pathology of Wilms' tumour (nephroblastoma): the International Society of Paediatric Oncology approach

(2009) G. M. Vujanic et al.   JOURNAL OF CLINICAL PATHOLOGY